The outcome in myasthenia gravis patients - An eight-year follow-up after finishing immunoabsorption therapy

Transfusion and Apheresis Science

Volumn 24, Issue 1, 2001, Pages 95-98

  Zettl, U K ^b   Winkler, R E ^a   Ramlow, W ^a   Tiess, M ^a   Michelsen, A ^a   Hebestreit, G ^a   Prophet, H ^a   Patow W ^a   Benecke, R ^b  

^a Dialyse Gemeinschaft Nord eV   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Immunoabsorption; Lymphocytes; Myasthenia gravis; Protein A; Therapeutic apheresis; Thymoma

Indexed keywords

AZATHIOPRINE; PREDNISOLONE; PROTEIN A; PYRIDOSTIGMINE;

APHERESIS; CASE REPORT; CONFERENCE PAPER; FOLLOW UP; HUMAN; IMMUNOADSORPTION; MYASTHENIA GRAVIS; THYMECTOMY; THYMOMA; TREATMENT OUTCOME;

ADULT; ANTIBODIES; BLOOD COMPONENT REMOVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; SALVAGE THERAPY; STAPHYLOCOCCAL PROTEIN A; TREATMENT OUTCOME;

EID: 0035168810     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(00)00125-9     Document Type: Conference Paper

References (8)

1. Myasthenia gravis and Lambert-Eaton Myasthenic Syndrome
2. Myasthenia gravis: Recognition of a human autoantigen at the molecular level
3. Myasthenia gravis: Difference between thymoma associated antibodies and cross-striational skeletal antibodies
4. Myasthenia gravis: Long term correlation of binding and Bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity
5. Immunoabsorption bei myasthenia gravis
6. Therapeutic apheresis in myasthenia gravis patients: A six-year follow-up